Clinical Efficacy and Prognostic Impact of Radioactive 125I Seed Implantation in the Treatment of Patients with Tumor Bone Metastasis
Objective To investigate the clinical efficacy and prognosis of radioactive iodine 125I seed implantation in the treatment of patients with bone metastasis.Methods 42 patients with bone metastases after malignant tumor surgery in People's Hospital of Ningxia Hui Autonomous Region from May 2020 to June 2023 were selected.All patients were treated with 125I seed implantation.The short-term efficacy,improvement of visual analogue scale(VAS)and Karnofsky score(KPS).3 months after operation,progression free survival(PFS),overall survival(OS),overall survival rate and adverse reactions were compared.Results The median number of target particle implantation was 26 in 42 patients with tumor metastasis.The average matched peripheral dose was(118.75±6.58)Gy,the objective response rate was 52.38％,and the disease control rate was 73.81％.After 3 months of treatment,the VAS score was lower than that before treatment,and the degree of pain was lighter than that before treatment(P all＜0.05);KPS score higher than before treatment,and functional status better than before treatment(P all＜0.05).The follow-up visit up to December 2023,the shortest PFS time of 42 patients was 5 months,the longest PFS time was 19 months,and the median PFS time was 11.56(95％CI:7.2-15.1)months.The median OS time was 21.6(95％CI:15.7-26.8)months,and the overall survival rate was 47.62％.There were only mild adverse reactions such as slight bleeding of needle path,low fever and local hematoma after operation.Conclusion Radioactive 125I seed implantation can improve the lesion control rate of patients with tumor bone metasasis,reduce the degree of cancer pain,improve quality of life or functional status,which is safe and reliable.
万方数据
